Education
About Us
Working with TipRanks
Follow Us
MacroGenics (MGNX)
NASDAQ:MGNX
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.73Last Year’s EPS
-0.84Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -14.76%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Neutral
MacroGenics achieved significant clinical and financial milestones in 2024, marked by a substantial increase in revenues and strong progress in clinical trials. However, increased net losses and operating expenses, along with the discontinuation of vobra duo, present challenges. The company remains financially stable with a solid cash position and is poised for future growth.Company Guidance
In the conference call, MacroGenics provided guidance and updates on their financial and clinical developments for the year 2024 while highlighting expectations for 2025. The company reported a total revenue of $150 million for 2024, a significant increase from $58.7 million in 2023, largely due to milestone achievements under the Incyte License Agreement. Research and development expenses rose to $177.2 million, up from $166.6 million in the previous year, reflecting increased costs related to their ADC pipeline and clinical trials. Cash, cash equivalents, and marketable securities totaled $201.7 million at the end of 2024, ensuring a cash runway into the second half of 2026. Clinically, MacroGenics provided updates on their investigational therapies, including the completion of enrollment in the 150-patient LORIKEET Phase 2 trial for lorigerlimab and plans to initiate the LINNET Phase 2 study in mid-2025. Additionally, three ADC molecules are in various stages of development, with MGC026 and MGC028 in clinical trials and MGC030 in preclinical studies. The company is also advancing MGD024, a bi-specific DART molecule, with ongoing Phase 1 studies.Significant Revenue Growth
MacroGenics reported a total revenue of $150 million for the year ended December 31, 2024, compared to $58.7 million in 2023, primarily due to milestones achieved under the Incyte License Agreement.
Clinical Milestones in 2024
MacroGenics completed enrollment in the LORIKEET Phase 2 trial for lorigerlimab and initiated the LINNET Phase 2 study. The company also advanced its ADC portfolio with MGC026, MGC028, and MGC030.
Strong Financial Position
Cash, cash equivalents, and marketable securities balance was $201.7 million as of December 31, 2024, with projections extending the cash runway into the second half of 2026.
Successful Asset Sale
Completed the sale of MARGENZA to TerSera Therapeutics, yielding a $36.3 million gain and providing non-dilutive capital.
---
MGNX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MGNX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $2.10 | $2.00 | -4.76% |
| Nov 05, 2024 | $3.77 | $4.19 | +11.14% |
| Aug 06, 2024 | $3.64 | $3.38 | -7.14% |
| May 09, 2024 | $14.67 | $3.31 | -77.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does MacroGenics (MGNX) report earnings?
MacroGenics (MGNX) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is MacroGenics (MGNX) earnings time?
MacroGenics (MGNX) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MGNX EPS forecast?
MGNX EPS forecast for the fiscal quarter 2025 (Q1) is -0.73.
---